Literature DB >> 24813709

Akt-ing up on SRPK1: oncogene or tumor suppressor?

Alex Toker1, Y Rebecca Chin2.   

Abstract

In this issue of Molecular Cell, Wang et al. (2014) report that the splicing kinase SRPK1 can function as both an oncogene and a tumor suppressor by modulating the activation state of the protein kinase Akt. This is shown to be mediated by the ability of SRPK1 to bind to the Akt phosphatase PHLPP1.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24813709      PMCID： PMC4089875          DOI： 10.1016/j.molcel.2014.04.020

Source DB:  PubMed          Journal:  Mol Cell        ISSN： 1097-2765            Impact factor:   17.970


  11 in total

1.  The Akt-SRPK-SR axis constitutes a major pathway in transducing EGF signaling to regulate alternative splicing in the nucleus.

Authors:  Zhihong Zhou; Jinsong Qiu; Wen Liu; Yu Zhou; Ryan M Plocinik; Hairi Li; Qidong Hu; Gourisanker Ghosh; Joseph A Adams; Michael G Rosenfeld; Xiang-Dong Fu
Journal:  Mol Cell       Date:  2012-06-21       Impact factor: 17.970

Review 2.  Turning off AKT: PHLPP as a drug target.

Authors:  Alexandra C Newton; Lloyd C Trotman
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014       Impact factor: 13.820

Review 3.  Conflicting roles of molecules in hepatocarcinogenesis: paradigm or paradox.

Authors:  Gen-Sheng Feng
Journal:  Cancer Cell       Date:  2012-02-14       Impact factor: 31.743

4.  PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms.

Authors:  John Brognard; Emma Sierecki; Tianyan Gao; Alexandra C Newton
Journal:  Mol Cell       Date:  2007-03-23       Impact factor: 17.970

5.  Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas.

Authors:  Gregory M Hayes; Patricia E Carrigan; Laurence J Miller
Journal:  Cancer Res       Date:  2007-03-01       Impact factor: 12.701

6.  Phosphoproteomics screen reveals akt isoform-specific signals linking RNA processing to lung cancer.

Authors:  Ioannis Sanidas; Christos Polytarchou; Maria Hatziapostolou; Scott A Ezell; Filippos Kottakis; Lan Hu; Ailan Guo; Jianxin Xie; Michael J Comb; Dimitrios Iliopoulos; Philip N Tsichlis
Journal:  Mol Cell       Date:  2014-01-23       Impact factor: 17.970

Review 7.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations.

Authors:  Jeffrey A Engelman
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

8.  Both decreased and increased SRPK1 levels promote cancer by interfering with PHLPP-mediated dephosphorylation of Akt.

Authors:  Pingping Wang; Zhihong Zhou; Anchang Hu; Claudio Ponte de Albuquerque; Yu Zhou; Lixin Hong; Emma Sierecki; Masahiko Ajiro; Michael Kruhlak; Curtis Harris; Kun-Liang Guan; Zhi-Ming Zheng; Alexandra C Newton; Peiqing Sun; Huilin Zhou; Xiang-Dong Fu
Journal:  Mol Cell       Date:  2014-04-03       Impact factor: 17.970

Review 9.  AKT/PKB signaling: navigating downstream.

Authors:  Brendan D Manning; Lewis C Cantley
Journal:  Cell       Date:  2007-06-29       Impact factor: 41.582

10.  Comprehensive molecular portraits of human breast tumours.

Authors: 
Journal:  Nature       Date:  2012-09-23       Impact factor: 49.962
View more
  10 in total

1.  The influence of SRPK1 on glioma apoptosis, metastasis, and angiogenesis through the PI3K/Akt signaling pathway under normoxia.

Authors:  Yingwei Chang; Qianqian Wu; Ting Tian; Li Li; Xuyan Guo; Zhuoying Feng; Junchen Zhou; Luping Zhang; Shuai Zhou; Guoying Feng; Fengchan Han; Jun Yang; Fei Huang
Journal:  Tumour Biol       Date:  2015-04-03

2.  The crucial role of SRPK1 in TGF-β-induced proliferation and apoptosis in the esophageal squamous cell carcinomas.

Authors:  Guohua Ren; Lijun Sheng; Haibo Liu; Yahong Sun; Yuji An; Yan Li
Journal:  Med Oncol       Date:  2015-06-23       Impact factor: 3.064

Review 3.  The double face of Morgana in tumorigenesis.

Authors:  Mara Brancaccio; Stefania Rocca; Laura Seclì; Elena Busso; Federica Fusella
Journal:  Oncotarget       Date:  2015-12-15

Review 4.  Therapeutic Applications of Targeted Alternative Splicing to Cancer Treatment.

Authors:  Jung-Chun Lin
Journal:  Int J Mol Sci       Date:  2017-12-28       Impact factor: 5.923

Review 5.  Alternative Splicing: Expanding the Landscape of Cancer Biomarkers and Therapeutics.

Authors:  Cláudia Bessa; Paulo Matos; Peter Jordan; Vânia Gonçalves
Journal:  Int J Mol Sci       Date:  2020-11-27       Impact factor: 5.923

6.  Rap1 Activity Is Essential for Focal Adhesion and Slit Diaphragm Integrity.

Authors:  Mee-Ling Maywald; Cara Picciotto; Carolin Lepa; Luisa Bertgen; Farwah Sanam Yousaf; Andrea Ricker; Jürgen Klingauf; Michael P Krahn; Hermann Pavenstädt; Britta George
Journal:  Front Cell Dev Biol       Date:  2022-03-18

Review 7.  RNA Splicing: A New Paradigm in Host-Pathogen Interactions.

Authors:  Komal Chauhan; Haroon Kalam; Ravi Dutt; Dhiraj Kumar
Journal:  J Mol Biol       Date:  2019-03-08       Impact factor: 5.469

8.  TrkC Is Essential for Nephron Function and Trans-Activates Igf1R Signaling.

Authors:  Carolin Lepa; Sascha Hoppe; Antje Stöber; Boris V Skryabin; Laura Katharina Sievers; Barbara Heitplatz; Giuliano Ciarimboli; Ute Neugebauer; Maja T Lindenmeyer; Clemens D Cohen; Hannes C A Drexler; Peter Boor; Thomas Weide; Hermann Pavenstädt; Britta George
Journal:  J Am Soc Nephrol       Date:  2020-12-30       Impact factor: 10.121

9.  A Multi-Breed Genome-Wide Association Analysis for Canine Hypothyroidism Identifies a Shared Major Risk Locus on CFA12.

Authors:  Matteo Bianchi; Stina Dahlgren; Jonathan Massey; Elisabeth Dietschi; Marcin Kierczak; Martine Lund-Ziener; Katarina Sundberg; Stein Istre Thoresen; Olle Kämpe; Göran Andersson; William E R Ollier; Åke Hedhammar; Tosso Leeb; Kerstin Lindblad-Toh; Lorna J Kennedy; Frode Lingaas; Gerli Rosengren Pielberg
Journal:  PLoS One       Date:  2015-08-11       Impact factor: 3.240

Review 10.  The potential of microRNAs in personalized medicine against cancers.

Authors:  Anne Saumet; Anthony Mathelier; Charles-Henri Lecellier
Journal:  Biomed Res Int       Date:  2014-08-28       Impact factor: 3.411
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.